Thrombosis: New culprits in an old disorder

Panminerva Medica

Volumn 44, Issue 2, 2002, Pages 107-113

  Federman, D G ^a,b   Moriarty, J P ^a,b   Kravetz, J D ^a,b   Kirsner, R S ^c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Venous thrombosis, etiology; Venous thrombosis, genetics; Venous thrombosis, therapy

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; FEMALE; GENETICS; HUMAN; HYPERHOMOCYSTEINEMIA; METABOLISM; MUTATION; PREGNANCY; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULANTS; CONTRACEPTIVES, ORAL; FACTOR V; FACTOR VIII; FACTOR XI; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; MUTATION; PREGNANCY; PROTHROMBIN; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0036618331     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Goldhaber SZ. Epidemiology of pulmonary embolism and deep vein thrombosis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG, editors. Haemostasis and thrombosis. New York, NY: Churchill Livingstone, 1994:1327.
2. Virchow R. Phlogose und Thrombose in Gefassystem. In: Virchow R, editor. Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Berlin: Meidinger Sohn und Co, 1856.
3. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrhag 1965;13:516-30.
4. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68(5):1370-3.
5. Schwartz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood 1984;64:1297-300.
6. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep venous thrombosis. N Engl J Med 1990;323:1512-6.
7. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999;353:1348-53.
8. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C; prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
9. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
10. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993;82:1989-93.
11. Koster T, Rosendaal FR, De Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
12. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
13. Svensson PJ, Zoller B, Mattiasson I, Dahlback B. The factor V R506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 1997;241:379-85.
14. Ozbek U, Tsangun Y. Frequency of factor V Leiden in Turkey. Int J Hematol 1996;64:291-2.
15. Rosendaal FR, Koster T, Vandenbrouke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
16. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
17. Montaruli B, Schinco P, Pannocchia A, Giorgianni A, Borchiellini A, Tamponi G et al. Use of modified functional assays for activated protein C resistance in patients with basally prolonged apt. Thromb Haemost 1997;78:1042-8.
18. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variant in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and in increase in thrombosis. Blood 1996;88:3698-703.
19. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997;78:1430-3.
20. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol 1997;98:907-9.
21. Cumming AM, Keeney S, Salden A, Bhavani G, Shwe KH, Hay CR. The prothrombin gene G.20210A variant: prevalence in a UK anticoagulant clinic population. Br J Haematol 1997;98;353-5.
22. Hillarp A, Zoller B, Svensson PH, Dahlback B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep vein thrombosis. Thromb Haemost 1997;78:990-2.
23. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-8.
24. Angchaisuksiri P, Pingsuthiwong S, Aryuchai K, Busabaratana M, Sura T, Atichartakarn V et al. Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population. Am J Hematol 2000;65(2):119-22.
25. Vicente V, Gonzalez-Conejero R, Rivera J, Corral J. The prothrombin gene variant 20210A in venous and arterial thromboembolism. Haematologica 1999;84:355-62.
26. Margaglione M, Branacaccio V, Giuliani N, D'Andrea G, Cappucci G, Iannaccone L et al. Increased risk for venous thrombosis in carriers of the prothrombin G to A 20210 gene variant. Ann Intern Med 1998;129:89-93.
27. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpainter K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1997;92:2800-2.
28. Simioni P, Prandoni P, Lensing AW, Scudeller C, Prins MH, Villalta S. The risk of recurrent venous thrombembolism in patients with an Arg 506 to Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399-403.
29. Eichinger S, Pabinger I, Stumpflen A, Hirschl M, Bialonczyk C, Schneider B et al. The risk of recurrence of venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997;77:624-8.
30. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egeberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers of the G1991A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999;81:684-9.
31. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and G20210A prothrombin mutation. N Engl J Med 1999;341:801-6.
32. Alpert MA. Homocyst(e)ine, atherosclerosis, and thrombosis. South Med J 1999;92:858-65.
33. Mudd SH. Skovby F. Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE et al. The natural history of homocystinuria due to cystathione β-synthetase deficiency. Am J Hum Genet 1985;37:1-31.
34. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullman D et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
35. Arnessen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
36. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollse SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
37. Wald NJ, Wyatt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease. Arch Intern Med 1998;158:862-7.
38. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
39. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ et al. Association between plasma homocysteine concentrations and extracranial carotid stenosis. N Engl J Med 1995;332:286-91.
40. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
41. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1996;334:759-62.
42. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998;80:874-7.
43. Fermo I, Viganò D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747-53.
44. den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans PW et al. Is hyperhomocysteinemia a risk factor for recurrent thrombosis? Lancet 1995;345:882-5.
45. Mandel H, Brenner B, Berant M, Rosenberg N, Lanier N, Jakobs C et al. Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis. N Engl J Med 1996;334:763-8.
46. Hankey GJ. Homocysteine and vascular disease. Lancet 1999;354:407-13.
47. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid, an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-21.
48. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501.
49. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342:374-80.
50. De Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ 1998;316:589-92.
51. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
52. Martinelli I, Sacchi E, Landi G, Taoli E, Duca F, Manucci M. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-7.
53. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;354:152-5.
54. Kyrle PA, Minar E, Hirschl M, Bialoncyzyk C, Stain M, Schneider B et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-62.
55. O'Donnell JO, Tuddenham EG, Manning R, Kimball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997;77:825-8.
56. Cumming AM, Shiach CR. The investigation and management of inherited thrombophilia. Clin Lab Haematol 1999;21:77-92.
57. Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thombosis. N Engl J Med 2000;342:696-701.
58. Middeldorp S, Meinardi JR, Koopman MM, van Pampus EC, Hamulyak K, van Der Meer J et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001;135:322-7.
59. Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001;135;367-73.